Low-field MRI lung opacity severity associated with decreased DLCO in post-acute Covid-19 patients.

Low-field MRI lung opacity severity associated with decreased DLCO in post-acute Covid-19 patients.

Publication date: Nov 01, 2024

To evaluate the clinical significance of low-field MRI lung opacity severity. Retrospective cross-sectional analysis of post-acute Covid-19 patients imaged with low-field MRI from 9/2020 through 9/2022, and within 1 month of pulmonary function tests (PFTs), 6-min walk test (6mWT), and symptom inventory (SI), and/or within 3 months of St. George Respiratory Questionnaire (SGRQ) was performed. Univariate and correlative analyses were performed with Wilcoxon, Chi-square, and Spearman tests. The association between disease and demographic factors and MR opacity severity, PFTs, 6mWT, SI, and SGRQ, and association between MR opacity severity with functional and patient-reported outcomes (PROs), was evaluated with mixed model analysis of variance, covariance and generalized estimating equations. Two-sided 5 % significance level was used, with Bonferroni multiple comparison correction. 81 MRI exams in 62 post-acute Covid-19 patients (median age 57, IQR 41-64; 25 women) were included. Exams were a median of 8 months from initial illness. Univariate analysis showed lung opacity severity was associated with decreased %DLCO (ρ = -0. 55, P = . 0125), and lung opacity severity quartile was associated with decreased %DLCO, predicted TLC, FVC, and increased FEV1/FVC. Multivariable analysis adjusting for sex, initial disease severity, and interval from Covid-19 diagnosis showed MR lung opacity severity was associated with decreased %DLCO (P

Concepts Keywords
Low 0.55 T
Mri Adult
Pulmonary Aged
Tlc COVID-19
Covid-19
Cross-Sectional Studies
DLCO
Female
Humans
Low-field MRI
Lung
Lung
Magnetic Resonance Imaging
Male
Middle Aged
Opacity severity
Post-Acute COVID-19 Syndrome
Pulmonary Diffusing Capacity
Respiratory Function Tests
Retrospective Studies
SARS-CoV-2

Semantics

Type Source Name
disease MESH Covid-19
disease MESH clinical significance
disease IDO symptom
disease MESH Long Covid
disease MESH Pulmonary Diffusing Capacity

Original Article

(Visited 1 times, 1 visits today)